[No evidence of fewer influenza complications with oseltamivir].
Since August 7th, treatment with neuraminidase inhibitors (oseltamivir) in the Netherlands has been limited to those patient groups who are considered at high risk of influenza-related complications. This policy is based on one study which shows only limited evidence of the effectiveness of neuraminidase inhibitors in lowering the number of such complications.
Bonneux
Luc
L
Nederlands Interdisciplinair Demografisch Instituut (NIDI/KNAW), Den Haag, The Netherlands. bonneux@nidi.nl
D000998:Antiviral Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D053139:Oseltamivir / Q000627:therapeutic use*; D011292:Premedication
D000998:Antiviral Agents; D053139:Oseltamivir